Efficacy and Safety of Ivarmacitinib, a Selective JAK1 Inhibitor, in Patients with Active Ankylosing Spondylitis: Results from an Adaptive Seamless Phase II/III Trial.
Liu X, Xu L, Zhao C, Liu S, Sun L, Yang L, Xu X, Wu R, Liu X, Zhang J, Xu S, Zhu P, Chen H, Wang X, Lin C, Lin J, Zhan F, Wei H, Huang Q, Liu H, Ma X, Shi G, Lu Y, Geng X, Jiang Z, Zhang N, Tang K, Zhang R, Zhao Y, Xue L, Song S, Shi X, Zhang Z, Liu P, Wang H, Li Z.
Liu X, et al. Among authors: xu l, xu s, xu x.
Arthritis Rheumatol. 2025 Jun 12. doi: 10.1002/art.43238. Online ahead of print.
Arthritis Rheumatol. 2025.
PMID: 40509748